{"id":"NCT00701636","sponsor":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","briefTitle":"Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery","officialTitle":"Pharmacokinetics of Daptomycin During Cardiopulmonary Bypass Surgery","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-07","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2008-06-19","resultsPosted":"2016-08-29","lastUpdate":"2016-08-29"},"enrollment":30,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Late Effects of Surgery","Staphylococcus Aureus","Surgical Site Infection"],"interventions":[{"type":"DRUG","name":"daptomycin","otherNames":["Cubicin"]}],"arms":[{"label":"Cases","type":"EXPERIMENTAL"},{"label":"Controls","type":"NO_INTERVENTION"}],"summary":"This investigation is a prospective, open-label pharmacokinetic study of daptomycin prophylaxis in patients undergoing coronary artery bypass graft surgery without valvular replacement.","primaryOutcome":{"measure":"Mean Daptomycin Concentrations at 12, 18, 24, and 48 h","timeFrame":"Hospital discharge or 7 days, whichever comes first","effectByArm":[{"arm":"Cases","deltaMin":22.7,"sd":9.7}],"pValues":[]},"eligibility":{"minAge":"19 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":7},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21444695"],"seeAlso":["http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3101392/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":[]}}